Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $14,513.58 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 527 shares of the business’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $27.54, for a total transaction of $14,513.58. Following the sale, the insider now owns 1,077,409 shares of the company’s stock, valued at $29,671,843.86. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Enliven Therapeutics Price Performance

NASDAQ ELVN opened at $27.53 on Friday. The company has a fifty day moving average price of $23.21 and a 200-day moving average price of $22.00. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -14.26 and a beta of 1.10. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $27.67.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, research analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC boosted its position in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares during the period. American Century Companies Inc. boosted its holdings in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares during the last quarter. EntryPoint Capital LLC bought a new position in Enliven Therapeutics during the first quarter valued at about $167,000. Finally, SG Americas Securities LLC bought a new position in Enliven Therapeutics during the third quarter valued at about $256,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ELVN has been the subject of a number of analyst reports. Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Robert W. Baird assumed coverage on Enliven Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $32.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.